MktsMarkets

Silexion Therapeutics Corp
NASDAQ: SLXNKey statistics
SLXN News
Stories mentioning SLXN from around the web — every one is an open thread, so give it a like or add your take.
Loading news…
Financial statements
As filed, straight from the 10-Q — up to 19 years of history, free, with every line item chartable.
| Line item | Q1 '26Mar 31 | Q4 '25Dec 31 | Q3 '25Sep 30 | Q2 '25Jun 30 | Q1 '25Mar 31 | Q4 '24Dec 31 | Q3 '24Sep 30 | Q2 '24Jun 30 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | ||||||||
| Cost of Goods Sold | ||||||||
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | ||||||||
| Research & Development | 1,370 | 3,375 | 2,157 | 1,018 | 590.00 | 871.00 | 3,217 | 766.00 |
| Sales General & Admin | ||||||||
| Total Operating Expenses | 2,749 | 4,406 | 3,292 | 2,284 | 1,650 | 1,900 | 8,036 | 1,385 |
| Operating Income (Loss) | (2,749) | (4,406) | (3,292) | (2,284) | (1,650) | (1,900) | (8,036) | (1,385) |
| Interest Income | ||||||||
| Interest Expense | ||||||||
| Other Expense | 4.00 | 6.00 | 4.00 | 0.00 | 3.00 | 2.00 | 3.00 | 2.00 |
| Pretax Income | (2,733) | (4,412) | (3,262) | (2,500) | (1,735) | (1,746) | (11,858) | (1,487) |
| Tax Provision | 0.00 | 3.00 | 1.00 | 2.00 | 2.00 | |||
| Net Income (Loss) | (2,733) | (4,412) | (3,262) | (2,503) | (1,735) | (1,747) | (11,860) | (1,489) |
| Earnings Per Share (Basic) | 0.85 | (3.32) | 2.88 | 4.32 | 3.84 | (41.60) | 274.25 | 197.80 |
| Earnings Per Share (Diluted) | 0.85 | (3.32) | 2.88 | 4.32 | 3.84 | (41.60) | 274.25 | 197.80 |
| Weighted Average Shares Outstanding (Basic) | 3,230 | 1,330 | 1,133 | 580.00 | 452.00 | 42.00 | 43.00 | 7.00 |
| Weighted Average Shares Outstanding (Diluted) | 3,230 | 1,330 | 1,133 | 580.00 | 452.00 | 42.00 | 43.00 | 7.00 |
Scroll the table sideways for older periods — the line-item column and the period header stay put. Hover a row and use the chart handle to plot it over the full history.
About SLXN
Silexion Therapeutics Corp (NASDAQ: SLXN) is a stock listed on the Nasdaq Stock Market under the ticker symbol SLXN. It last traded at $1.31 (Nov 20, 2026, 4:00 PM ET), down 12.7% on the day. That gives Silexion Therapeutics a market capitalisation of $850.9K.
Over the past 52 weeks SLXN has traded between $1.26 and $777.12.
For the quarter ended Mar 31, 2026 it reported a net loss of $2.7M.
| Quarter ended | Revenue | Net income |
|---|---|---|
| Mar 31, 2026 | — | -$2.7M |
| Dec 31, 2025 | — | -$4.4M |
| Sep 30, 2025 | — | -$3.3M |
| Jun 30, 2025 | — | -$2.5M |
From Silexion Therapeutics’s quarterly (10-Q) filings, in US dollars.
Take a break — play a market game
Seven free games built around the markets. No download, no sign-up: they run right here in your browser.
Latest News
Market news from around the web — every story is an open thread, so give it a like or add your take.
Loading news…